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ABSTRACT
Hepatocellular carcinoma (HCC) is a common liver disease that causes significant public 
health problems throughout the world, including in Indonesia. The HCC is the six most 
common cancers and second cancer-related deaths among men in the world. Recently 
it was reported that the microRNA is an important player in hepatocarcinogenesis.  The 
expression of MiRNA-200c is often regulated in primary HCC and HCC cell lines. Vascular 
endothelial growth factor-A (VEGF-A) is a regulator of angiogenesis that has been reported 
as miR-200c target gene. This study was conducted to measure expression levels in miR-
200c and mRNAVEGF-A and their potential role as biomarkers at HCC. A total of 36 
HCC patients and 36 healthy subjects were included in this study. The relative expression 
of miRNA-200c and mRNA VEGF-A was quantified using reverse transcription real time 
quantitative PCR (qRT PCR). Relative expression was calculated using . Unpaired t-test 
was used to compare the expression levels of circulating miRNA-200c and mRNA VEGF-A 
in HCC patients and healthy subjects. Pearson test was used to determine correlation 
between circulating miR-200c expression and mRNA VEGF-A expression levels. The 
expression levels of circulating miR-200c in HCC patients were lower compared to healthy 
subjects although it was not significant (p = 0.258). Conversely, the expression levels 
of circulating mRNA VEGF-A in HCC patients were significantly higher compared to 
healthy subjects (p = 0.001). The relative expression levels of circulating miR-200c were 
negatively correlated with mRNA VEGF-A in HCC patients. In conclusion, the expression 
levels of mRNA VEGF-A in HCC patients are significantly deregulated in compared to 
that in healthy subjects. Negative correlation between circulating miRN-200c and mRNA 
VEGF-A expression levels are reported in HCC patients.
ABSTRAK
Hepatocellular carcinoma (HCC) adalah penyakit hati yang umum dan menyebabkan 
masalah kesehatan masyarakat yang signifikan di seluruh dunia, termasuk di Indonesia. 
Karsinoma hepatoseluler adalah penyebab kematian keenam akibat kanker umumnya 
dan  kedua pada laki-laki di seluruh dunia. Saat ini microRNA dilaporkan  berperan 
penting dalam hepatokarsinogenesis. Ekspresi MiRNA-200c mengalami deregulasi pada 
jaringan HCC primer dan sel HVCC. Vascular endothelial growth factor-A (VEGF-A) 
adalah regulator angiogenesis yang dilaporkan sebagai gen target miR-200c. Penelitian 
ini dilakukan untuk mengkaji ekspresi miR-200c dan mRNA VEGF-A serta peran 
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potensialnya sebagai biomarker HCC. Sebanyak 36 pasien HCC dan 36 subjek sehat 
diambil dalam penelitian ini. Ekspresi relatif mRNA miRNA-200c dan VEGF-A diukur 
menggunakan reverse transcription real time quantitative PCR (qRT PCR). Ekspresi relatif 
dihitung menggunakan . Uji t tidak berpasangan digunakan untuk membandingkan tingkat 
sirkulasi miRNA-200c dan mRNA VEGF-A pasien HCC dan subjek sehat. Uji Pearson 
digunakan untuk menentukan korelasi antara sirkulasi ekspresi miR-200c dan tingkat 
ekspresi mRNA VEGF-A. Tingkat ekspresi miR-200c yang bersirkulasi pada pasien HCC 
lebih rendah dibandingkan dengan subjek sehat meskipun tidak bermakna (p = 0.258). 
Ekspresi level sirkulasi mRNA VEGF-A lebih tinggi secara bermakna dibandingkan subjek 
sehat (p = 0.001). Tingkat ekspresi relatif miR-200c dalam sirkulasi memiliki hubungan 
negatif dengan VEGF-A mRNA pada pasien HCC. Dapat disimpulkan, tingkat ekspresi 
mRNA VEGF-A mengalami deregulasi secara bermakna pada pasien HCC dibandingkan 
pada subjek sehat. Ada hubungan negatif  antara tingkat ekspresi miRN-200c dalam 
sirkulasi dan mRNA VEGF-A pada pasien HCC.
Keywords: blood plasma - hepatocellular carcinoma - miR-200c - mRNA VEGF-A - 
biomarker
INTRODUCTION
Cancer is a non-infectious disease with 
significant impacts on  overall morbidity 
and mortality in the world.1 It was estimated 
in 2018 there are 18 million new cancer 
cases, 9 million cancer associated mortality 
worldwide. Hepatocellular carcinoma (HCC) 
is the most common cause of cancer deaths 
in the world (9.1% of total cancer related 
deaths or 746,000 in the world).1 The HCC 
is also one of the problems in Indonesia, 
especially in males, with the second average 
mortality rate of 12,654 people/5 years. It 
is predicted to increase due to delays in the 
diagnosis, limitations of diagnostic methods 
and treatment.1 
The development of early diagnostic 
methods for HCC has been widely applied. 
However, these current methods have 
some limitations in the practice.2 Indonesia 
generally adopts the HCC diagnostic method 
based on the Asian-Pacific Association 
for the Study of the Liver (APASL). It is 
performed with observation of the typical 
vascular pattern of arterial enhancement with 
portal-venous washout obtained by dynamic 
computed tomography, dynamic magnetic 
resonance imaging or contrast enhanced 
ultrasonography.3 The achievement of 5-year 
survival rate is still low only about 20% of 
all cases. This generally associated with late 
diagnosis of the HCC when the cancer has 
entered the advanced stage.4 
MicroRNA is a class of small non-
coding RNA molecule (22-24 nucleotides-
long) that functions as a post-transcriptional 
regulator of protein coding gene expression. 
MicroRNA can bind to one or more mRNAs 
and cause the degradation and/or inhibition 
of protein translation.4 About 30% of protein 
coding genes are known to be widely 
regulated by microRNAs.5,6
Dysregulation of microRNA expression 
has been identified in a variety of human 
cancers. This dysregulation is associated 
with clinical and biological functions 
specific to the process of carcinogenesis 
included HCC.6,7 Many studies have shown 
that microRNA can potentially be a clinical 
diagnostic biomarker because it has a 
high degree of stability and can describe a 
biological change especially in cancer.8,9 
MicroRNA dysregulation can be detected 
in several ways using tissue, serum, plasma, 
or urine samples. High levels of stability in 
extracellular microRNAs can be encountered 
in body fluids especially plasma. MicroRNA 
can be used as non-invasive markers for HCC 
detection, prognostic and predict therapeutic 
response.8
Several microRNAs dysregulation 
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contribute to the pathogenesis of HCC. One 
of the microRNAs dysregulation reported 
in HCC is the miR-200 family. MiR-200c 
is downregulated in HCC tissue and it is 
associated with low survival rate of HCC 
patients in the early stages.10  Decrease of 
miR-200c expression affects the expression 
of several oncogenes, such as Vascular 
Endothelial Growth Factor A (VEGF-A). 
An in vitro study reported VEGF-A, 
protein expression and cell proliferation 
significantly increased in HCC cells.11 
VEGF is a class of protein growth factor that 
plays a role in the angiogenesis of cancer 
cells, not only for the development of new 
blood vessels but also for the development 
of some types of cancer tissue.12 Cancer 
cells produce angiogenic proteins such 
as VEGF that stimulates endothelial cells 
proliferation and migration.13 Angiogenesis 
widely contributes in many cancer cells 
growth included HCC. The vascular 
endothelial cells develop at this stage when 
the tumor lesion has exceeded 0.5 mm. 
VEGF plays an important role in promoting 
of the endothelial cells proliferation, thus 
supporting neovascularization in and around 
cancer tissues.14 The study aimed to measure 
expression levels in miR-200c and mRNA 
VEGF-A of HCC. The results of this study 
will be useful in the development of these 
genes as biomarker candidates of HCC. 
MATERIALS AND METHODS
Design and sample collection
This was a cross sectional study using 
plasma samples from 36 new HCC patients 
in Dr. Sardjito General Hospital, Yogyakarta 
and Prof. DR. Margono Soekarjo General 
Hospital, Purwokerto. As control 36 plasma 
samples of healthy subjects obtained from 
Blood Bank Center of Dr. Sardjito General 
Hospital, Yogyakarta were used.
The inclusion criteria for HCC patients 
were new diagnosed with HCC, no history of 
other cancer, never received chemotherapy 
and radiotherapy, willing to participate in 
study, and the patient’s clinical condition 
allowed to be taken his blood. The inclusion 
criteria for the healthy subjects were no 
history of HCC and other cancers, no family 
history of HCC, age 25-70 years, HBsAg 
negative, and no HBV and HCV infection 
history. The exclusion criteria were resigned 
as the respondent, and the patient’s condition 
did not allow for blood sampling.
Total RNA extraction
About 5-6 mL of venous blood sample 
were taken and put into 2 EDTA tube 
vacutainer and then centrifuged at 1500 rpm 
for 10 min to obtain plasma sample. The 
plasma was then stored in the refrigerator 
at -80 oC. Total RNA was isolated from 
200 μL of plasma using miRCURY RNA 
Isolation Kit-Biofluid (Cat No.300112, 
Exiqon) according to the kit procedure. Total 
RNA was then stored at  -80 oC until cDNA 
synthesis. 
qRT-PCR 
As much as 4 µL the RNA isolated from 
plasma was used for cDNA synthesis using 
Universal cDNA Synthesis kit II, 8-64 rxns 
(Cat No.203301, Exiqon) according to the kit 
procedure. qRT-PCR was performed using 
ExiLent SYBR Green PCR master mix, 2.5 
mL (Cat No. 203402, Exiqon) and specific 
microRNA primer (Exiqon), and cDNA 
template. The qRT PCR was performed 
using the Bio-rad Thermal Cycler CFX96 
Real Time System (Bio-rad, USA). The qRT-
PCR reaction was performed for 40 cycles 
with procedure as follow : predenaturation 
at 95°C for 10 min, followed by denaturation 
of 95°C for 10 sec, annealing, extension, 
and data measurement at 58°C for 1 min. 
Melting curve and melt peak curve analysis 
were performed to determine the specificity 
of the PCR product. method was used to 
measure miR-200c expression on plasma 
of HCC compared to healthy subjects with 
miR-16 used as reference gene in relative 
quantification of miR-200c expression. 
Quantification of VEGF-A mRNA 
expression was performed by the One-Step 
qRT-PCR method using Bioline One-Step 
qRT-PCR master mix kit, VEGF-A mRNA 
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primer set (forward and reverse), RNA 
sample according to the kit procedure.  was 
used to calculate the relative quantification 
of VEGF-A mRNA expression between 
plasma of hepatocellular carcinoma patients 
and healthy subjects. Beta actin mRNA 
TABLE 1. Primersequence for mRNA VEGF-A and mRNA ACTB
Gen Forward Reverse Product length
VEGF-A 5’TGCAGATTATGCGGATCAAACC3’ 5’TGCAATCACATTTGTTGTGCTGTA3’ 80 bp
ACTB 5’GGGAATTCAAAACTGGAACGGT-
GAAGG3’
5’GGAAGCTTATCAAAGTCCTCGGCCA-
CA3’
136 bp
TABLE 2. Relationship between expressions of miR-200c based on clinicopathological 
characteristic of HCC patient
Characteristic HCC
p-Valuen Expression of miR-
200c (Mean±SD)
Age (n=36)
•	 ≤ 50 7 7.90 ± 1.53 0.057
•	 >50 6 9.73 ± 1.55
BCLC stage (n=29)
•	 Early stage 3 9.54 ± 1.75 0.679
•	 Advance stage 8 9.11 ± 1.38
(ACTB) was used as a reference gene for 
quantification of VEGF-A mRNA expression. 
The primer sequences of VEGF-A mRNA 
and ACTB mRNA used in this study were 
shown in  TABLE 1.
Expression analyzers miR-200c and 
VEGF-A mRNAs used Biorad CFX Manager 
TM Software to determine the value of 
quantification cycle (Cq), amplification 
curve, melting curve, melt peak curve from 
qRT-PCR results. The expression changes 
of miR-200c and VEGF mRNA in plasma 
of HCC patients and healthy subjects were 
calculated using the Livak Method formula.
Statistical analysis
Data were presented as mean ± standard 
deviation (SD). Unpaired t-test was used 
to evaluate the differences of miR-200c 
and VEGF-A mRNA expressions between 
HCC patients and healthy subjects. One way 
Anova were used for more than 2 groups 
of sub-analyzes of respondents’ clinical 
characteristics included age, history of 
cirrhosis, history of HBV infection, HCV 
infection and BCLC stage. The correlation 
between miR-200c expression with 
VEGF-A mRNA expression was analyzed 
using Pearson correlation analysis.  p value 
<0.05 and 95% confidence interval (CI) was 
considered significant. 
RESULTS
Relationship between expression of 
miR-200c with characteristics and 
clinicopathology of HCC patients
Relationship between expressions of 
miR-200c based on clinicopathological 
characteristic of HCC patient was presented 
in TABEL 2. 
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Gender (n=36)
•	 Male 8 8.80 ± 1.94 0.893
•	 Female 5 8.66 ± 1.63
Smoking history (n=29)
•	 Yes 3 9.99 ± 0.93 0.297
•	 No 8 8.94 ± 1.50
Alcohol consumption (n=29)
•	 Yes 1 7.95 ± 0 0.368
•	 No 10 9.36 ± 1.41
Hepatitis (n=33)
•	 Yes 7 8.86 ± 1.91 0.896
•	 No 5 9.00 ± 1.60
Cirrhosis hepar (n=29)
•	 Yes 3 8.61 ± 1.21 0.401
•	 No 8 9.46 ± 1.48
AFP (ng/ml) (n=31)
•	 < 200 6 9.29 ± 1.60 0.476
•	 >200 6 8.55 ± 1.89
Nodul (n=28)
•	 Single 5 8.42 ± 2.14 0.419
•	 Multiple 7 9.28 ± 1.40
TACE (n=29)
•	 Pre 4 9.62 ± 1.74 0.512
•	 Post 7 9.00 ± 1.28
Metastasis (n=32)
•	 Yes 4 7.52 ± 1.62 0.038*
•	 No 8 9.62 ± 1.34
The miR-200c expression showed 
significantly deference between the 
metastasis groups compared to the non-
metastatic group (p <0.05). The relative 
expression of miR-200c in the metastasis 
group (ΔCq = 7.52 ± 1.62) was significantly 
higher than the relative expression of miR-
200c in the non-metastatic group (ΔCq = 9.62 
± 1.34). However, the relative expression 
of miR-200c did not differ significantly on 
the basis of other sociodemographic and 
clinicopathologic characteristics.
Expression of microRNA-200c in blood 
plasma of HCC patient and healthy 
subject
To evaluate the factors that influence 
the loss of miR-200c expression on 
blood plasma of HCC patients, a logistic 
regression analysis was performed based 
on sociodemographic and clinicopathologic 
characteristics as shown in TABLE 3.
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The variables in the equation of 
independent variables, p value of wald test 
had significance > 0.25. Those value of HBV 
(p = 0.065) and nodule (p = 0.245) meant 
that each variable of HBV and nodule had 
significant partial influence to loss of miR-
200c expression on HCC patients. The 
quantification results of the fold change 
expression miR-200c in the blood plasma of 
HCC patients compared to blood plasma of 
healthy subjects shown in TABLE 4.
TABLE 3. Logistic regression analysis of miR-200c expression that detected and undetected 
in blood plasma of HCC patients (n=36)
85% C.I Exp(B)
Parameter B Stand. err Wald df Sig Exp(B) Lower Upper
HBV -3.047 1.648 3.417 1 0.065 0.047 0.002 1.201
Multiple nodul -0.761 0.654 1.35 1 0.245 0.467 0.130 1.684
TABLE 4. Relative expression of miR-200c in the blood plasma of hepatocellular carcinoma 
patient compared to healthy subject (n=26)
Sampel ∆Cq miR-200c (Mean±SD) ∆∆Cq miR-200c Fold Change(2-∆∆Cq)
HCC(n=13) 8.75 ± 1.75
0.89 0.53
Healthy subject(n=13) 7.8 ± 2.11
The value of 2-∆∆Cq was less than 1 (0.53), 
then the calculation of fold change was 
continued by using the calculation  with the 
result of 1.85. It could be concluded that the 
miR-200c expression in the blood plasma of 
HCC patients was down regulated 1.85-fold 
compared to that of healthy subjects. 
The difference of relative expression 
(ΔCq) miR-200c plasma between HCC 
patients and healthy subjects was showed by 
TABLE 5. No significant difference in the 
relative expression of miR-200c in the blood 
plasma between HCC patients and healthy 
subjects was observed (p>0.05). 
TABLE 5. Comparison test between relative expression of miR-200c in the 
blood plasma of HCC patients and healthy subjects (n=26)
Group ∆Cq miR-200c (Mean±SD) p
HCC (n=13) 8.75 ± 1.75
0.258*
Healthy subject (n=13) 7.6 ± 2.11
Expression of mRNA VEGF-A in blood 
plasma of HCC patients and healthy 
subjects
The expression of mRNA VEGF-A in 
blood plasma of HCC patients and healthy 
subjects was showed in TABLE 6. The 
expression of VEGF-A mRNA in the blood 
plasma of HCC patients increased 4.42 fold 
compared to healthy subjects.
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The difference in the relative expression 
(ΔCq) of VEGF-A mRNA between HCC 
patients and healthy subject showed in 
TABLE 7. A significant difference in relative 
expression (ΔCq) of VEGF mRNA between 
blood plasma of HCC patients and healthy 
subjects was observed (p<0.001). The 
lower the ΔCq value, the higher the mRNA 
expression. It can be interpreted that the 
relative expression of mRNA VEGF-A was 
significantly upregulated in plasma of HCC 
patients compared to that in healthy subjects.
TABLE 6. Relative expression of mRNA VEGF-A in the blood plasma of HCC and 
healthy subjects (n=72)
Group ∆Cq mRNA VEGF (Mean±SD) ∆∆Cq mRNA VEGF 2-∆∆Cq
HCC(n=36) -0.95 ± 1.97
-2.14 4.42
Healthy subject (n=36) 1.19 ± 1.80
TABLE 7. Comparison test between relative expression of mRNA VEGF-A in the 
blood plasma of HCC and healthy subject (n=72)
Group ∆Cq mRNA VEGF (Mean±SD) P
HCC(n=32) -0.95 ± 1.97
<0.001*
Healthy subject(n=25) 1.19 ± 1.80
Correlation between expression miR-200c 
and VEGF-A mRNA in blood plasma
TABLE 8 shows the correlation between 
miR-200c expression and VEGF-A mRNA 
expression in HCC patients and healthy 
subjects. The relative expression of miR-
200c in blood plasma of HCC patients (p 
= 0.576) and also in healthy subjects (p = 
0.874) were not correlated with the relative 
expression of VEGF-A mRNA. However, it 
appeared that the relative expression of miR-
200c and VEGF-A mRNA had a negative 
correlation.  It shown that the lower the 
relative expression of miR-200c, the higher 
the relative expression of VEGF-A mRNA 
was observed. Furthermore, the higher the 
relative expression miR-200c, the lower the 
relative expression of VEGF-A mRNA was 
observed.
TABLE 8. Correlation between miR-200c expression and VEGF-A mRNA 
expression
Variable ∆Cq mRNA VEGF-A
(mean ± SD)
p r
∆Cq miR-200c
(mean ± SD)
HCC HCC
8.75 ± 1.75 -0.95 ± 1.97 0.576 -0.171
Healthy subject Healthy subject
7.86 ± 2.11 1.19 ± 1.8 0.874-0.049
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DISCUSSION
Hepatocellular carcinoma development 
takes a long time with accumulation changes 
in the genetic and epigenetic levels that lead 
to oncogenes activation or inactivation of 
tumor suppressor genes. In terms of sex, 
the majority of HCC patients were males as 
many as 23 people and females as many as 
13 people which mean having a 2:1 ratio with 
only one of the most dominant risk factors is 
the majority of HCC patients infected with 
hepatitis B virus. The HCC patients with 
various risk factors such as being in endemic 
areas of hepatitis, alcoholics, smokers, 
cirrhosis, aflatoxin contamination and age, 
male and female comparison rates to 4:1.15 
The dominance of male HCC patients is in 
line with the high mortality rate of HCC 
patients that majority is males in pacific Asia. 
The dominant age range of HCC patients in 
both men and women was ≥50 years age 
group (69.4%). In addition, the incidence of 
HCC in Asia-pacific increased both men and 
women aged ≥40 years.16
The HCC patients in this study were 
diagnosed at an early stage (BCLC B) of 9 
people (32.7%) and advanced stage (BCLC 
C and BCLC D) were 20 (52.6%). In this 
study, no HCC patients were diagnosed with 
BCLC A stage. At very early stage of HCC, 
one-third of patients showed no specific 
symptoms when examined and only a quarter 
complained of discomfort and abdominal 
pain. Advanced stages are characterized by 
the presence of extra hepatic spread, vascular 
invasion, and the presence of cancer-related 
symptoms.17
In this study, the majority of HCC 
patients were also positively infected with 
the hepatitis B virus. The hepatitis B is the 
most dominant risk factor for HCC cases. 
Approximately 60-80% of people with 
hepatitis B infection developed into HCC in 
Asia.18 In Indonesia as one of the developing 
countries in Asia, the incidence of HBV 
infection is at a high percentage of about 
8% of the population.19 In this study the 
incidence of cirrhosis only 9 people (31%) 
the rest of the results of the examination did 
not contain cirrhosis. In theory, about 80% to 
90% of patients with cirrhosis can developed 
into HCC. Patients with chronic hepatitis B 
infection accompanied by cirrhosis may 
continue to develop into HCC, especially 
patients with hepatitis B virus that actively 
replicate.20
The majority of HCC patients 
experienced an increase in alpha fetoprotein 
(AFP) concentrations higher than the 
normal limit (≥200 ng / mL). The high AFP 
concentrations in HCC patients are associated 
with HCC patient status with hepatitis viral 
infection, especially hepatitis B virus. The 
upregulation and downregulation of AFP 
expression are closely related to BCLC 
status of HCC patients where in the early 
stages BCLC (O-A) concentration of AFP 
in normal limits.21 The study also looked 
at demographic and clinicopathologic 
characteristics that affected the loss of miR-
200c expression in 17 plasma samples of HCC 
patients using logistic regression. The HBV 
infection variable and the number of nodules 
have a significant partial effect on the loss 
of miR-200c expression in HCC. The loss 
of miR-200c expression in blood plasma of 
HCC patients was also reported by Okamoto 
et al.,22 where HCV and HBV were known 
to regulate microRNA expression through 
epigenetic mechanisms by the occurrence 
of DNA hypermethylation in many gen 
promoters. Specific mechanisms of how 
the regulation of miR-200c expression was 
reported by Vrba et al.23 In their study of 
DNA methylation of miR-200c and miR-141 
in CpG islands causing loss of expression 
miR-200c which is a class of suppressor 
tumors microRNAin cancer.
Multiple nodules in HCC patients may be 
derived from multiple primary HCC nodules 
and metastatic intrahepatic nodules. Research 
conducted by Ng et al.24 in HCC patients 
with multiple nodules found 36% of primary 
nodules and 64% of intrahepatic metastatic 
nodules. Previous studies have revealed 
that the miR-200 family has been shown to 
suppress the formation and growth of HCC 
cancer cells. In vitro study using melanoma 
cells revealed increased expression of miR-
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200c and miR-205 capable of inhibiting 
cancer formation.25 To support the growth of 
cancer cells requires angiogenesis activation 
for the formation of new blood vessels. The 
miR-200c is a negative regulator of VEGF 
expression at mRNA and protein levels.26 In 
studies using ovarian cancer cells, miR-200c 
suppresses the expression of fas-associated 
phosphatase-1 (FAP-1), thus increasing the 
expression of CD95 which is an apoptotic 
receptor, thus increasing the sensitivity of 
cells to apoptosis.27 
This study found that the relative 
expression of miR-200c in the blood plasma 
of HCC patients experienced downregulation 
of 1.85 times compared to that expression in 
healthy subjects. Previous studies have found 
that miR-200c expression in HCC tissues was 
downregulated compared to healthy tissue.6,10 
Research using circulating microRNA from 
serum HCC patients miR-200c is known to 
decrease expression than healthy individuals 
although not significantly different.28 This 
suggests that decreased expression of miR-
200c is one of the molecular mechanisms 
of the carcinogenesis process. The miR-
200 family including miR-200c is a tumor 
suppressor microRNA, where its down 
regulation or loss of expression contributes 
to the process of carcinogenesis and cancer 
progression with increased expression of the 
oncogenic protein.10 Research conducted by 
Li et al.29 found that decreased miR-200c 
expression in HCC tissue and line-cell was 
associated with increased oncogen mitotic 
arrest deficiency protein 2 (MAD2L). 
Down regulation of miR-200c expression 
in cancer cells contributes to the epithelial 
mesenchymal transition (EMT) process, 
migration, metastasis by direct targeting of 
E-cadherin mRNA to inhibit transcription 
pathways from ZEB1 and ZEB2.30
MicroRNA deregulation, especially 
microRNA downregulation can be due 
to interference of microRNA biogenesis 
process in cancer cell. Melo et al.31 revealed 
that mutations in the exportin-5 gene 
(XPO5) result in trapping of pre-miRNAs 
in the nucleus thus inhibiting the maturation 
of microRNAs in cancer cells. This study 
found the relationship between relative 
expression miR-200c with metastatic status 
of HCC patients. Metastasis is the spread 
of cancer cells originating from primary 
cancer tissue to the nearest organ or tissue 
of distant organs through blood vessels 
and lymphatic vessels.32 The miR-200c is 
known to regulate many genes that support 
angiogenesis, invasive, and metastasis. The 
VEGF-A, DLC1, ZEB1/ZEB2, FLT-1, KDR, 
VIM, PLCG1, NTRK2, NTF3, FN1, MSN 
genes are regulated by miR-200c proven to 
play a role in cancer progression.33 Panda et 
al.34 reported how miR-200c regulates the 
expression of VEGF-A. using ishikawa-
line cells (endometrial adenocarcinoma) 
increased miR-200cexpression followed by 
decreased expression of mRNA and VEGF-A 
protein. VEGF-A is a protein that plays an 
important role in the process of angiogenesis 
early in the development of cancer cells by 
supporting neovascularization of cancer 
tissue.
Deleted liver cancer-1 (DLC1) is a tumor 
suppressor gene and metastasis suppressor 
gene that govern the formation of actin and 
focal adhesion. The expression of DLC1 is 
also regulated by miR-200c.35 miR-200c 
also suppresses the expression of fibronectin 
1 (FN1), meosin (MSN), and leptin receptor 
(LEPR) so that cancer cell migration becomes 
inhibited.36 miR-200c is found to regulate 
the epithelial to mesenchymal transition 
process that supports metastasis with direct 
targeting mechanisms ZEB1 and ZEB2 
to suppress E-cadherin.36 In this study, the 
relative expression of VEGF-A mRNA was 
significantly upregulated in blood plasma of 
HCC patients by 4.42  fold compared to that 
in healthy subjects. This is consistent with the 
results in the previous studies that found that 
VEGF-A mRNA expression has increased in 
HCC tissue compared to normal tissue and 
is strongly associated with vascularization 
of cancer and mortality incidence.37 HCC 
patients with hepatitis B virus infection have 
increased VEGF-A mRNA expression and 
this correlates with recurrence after resection 
and mortality events in HCC patients.38
The correlation test results showed 
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that the relative expression of miR-200c 
was not significantly correlated with the 
relative expression of VEGF-A mRNA both 
in the blood plasma of HCC patients and of 
healthy subjects. In this study was found 
that miR-200c has the ability to regulate 
the expression of many protein coding 
genes, one of which is the VEGF-A gene. 
MicroRNA has the potential to regulate 
the expression of hundreds of genes, and 
one protein coding gene can be regulated 
by various microRNA. These contributions 
resulting many pathways to be cancer 
cells. There are currently over 1000 genes 
encoding microRNAs in the human genome, 
and the microRNAs play a role in regulating 
the expression of about 60% of the human 
protein coding gene.39
Not only  the expression of miR-
200c regulated by many factors but also 
the expression of VEGF-A mRNA. The 
miR200b expression in cancer cells is 
also known as the VEGF-A regulator by 
targeting VEGF-A directly and its receptor 
Flt1 and KDR. In experiment miR200b may 
act as an angiogenesis inhibitor in cancer 
cells.40 This opinion is in agreement with 
Yeh et al.10 found that 4 families of miR-
200 (miR-200a, miR-200b, miR-200c, 
and miR-141) acting as suppressor tumor 
genes decreased expression in HCC. Cancer 
cells in hypoxic conditions have increased 
regulation of VEGF expression for the 
purpose of angiogenesis. In experiment 
miR-20b is known to decrease the regulation 
of VEGF expression in cancer cells. MiR-
20b targeted directly at 3’UTR VEGF 
plays a role in regulating VEGF protein 
expression in cancer. MiR-125a directly 
regulates the expression of the VEGF-A 
gene at post transcription level by targeting 
the VEGF-A30 mRNA. In their experiment 
with restore the expression of miR-125a, it 
was able to inhibit the development of cancer 
malignancy significantly by decreasing the 
regulation of matrix metalloproteinase 11 
(MMP11) and VEGF-A expression both in 
vitro and in vivo.41 The presence of many 
other more dominant regulators in regulating 
VEGF-A gene expression besides miR-200c 
led to variations in the quantification results 
of relative expression of the two genes so no 
correlation was found between the relative 
expression of miR-200c and VEGF-A 
mRNA in blood plasma of HCC patients.
CONCLUSION
This study shows that the expression 
of miR-200c and VEGF-A mRNA can be 
detected and quantified in the blood plas-
ma of HCC. There is a downregulation of 
miR-200c expression and upregulation of 
VEGF-A mRNA expression between plasma 
of HCC patients compared to that healthy 
subjects. However, there is no significant 
correlation between miR-200c expression 
and VEGF-A mRNA expression in the blood 
plasma of HCC patients.
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